These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32723531)

  • 21. Depression is associated with poor functioning in activities of daily living among nursing home residents without cognitive impairment.
    Drageset J; Eide GE; Ranhoff AH
    J Clin Nurs; 2011 Nov; 20(21-22):3111-8. PubMed ID: 21592245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic accuracy of Parkinson's disease and atypical parkinsonism in nursing homes.
    Weerkamp NJ; Tissingh G; Poels PJ; Zuidema SU; Munneke M; Koopmans RT; Bloem BR
    Parkinsonism Relat Disord; 2014 Nov; 20(11):1157-60. PubMed ID: 25258327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.
    Oertel WH; Wolters E; Sampaio C; Gimenez-Roldan S; Bergamasco B; Dujardin M; Grosset DG; Arnold G; Leenders KL; Hundemer HP; Lledó A; Wood A; Frewer P; Schwarz J
    Mov Disord; 2006 Mar; 21(3):343-53. PubMed ID: 16211594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Complexity and Use of Antipsychotics and Restraints in Long-Term Care Residents with Parkinson's Disease.
    Heckman GA; Crizzle AM; Chen J; Pringsheim T; Jette N; Kergoat MJ; Eckel L; Hirdes JP
    J Parkinsons Dis; 2017; 7(1):103-115. PubMed ID: 27689617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
    Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
    J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications.
    Samuel M; Caputo E; Brooks DJ; Schrag A; Scaravilli T; Branston NM; Rothwell JC; Marsden CD; Thomas DG; Lees AJ; Quinn NP
    Brain; 1998 Jan; 121 ( Pt 1)():59-75. PubMed ID: 9549488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.
    Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Schelosky L; Tison F; Rascol O
    JAMA Neurol; 2014 Jul; 71(7):884-90. PubMed ID: 24839938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of characteristics affecting instrumental activities of daily living in Parkinson's disease patients without dementia.
    Choi SM; Yoon GJ; Jung HJ; Kim BC
    Neurol Sci; 2019 Jul; 40(7):1403-1408. PubMed ID: 30931509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson's disease.
    Mitchell SL; Kiely DK; Kiel DP; Lipsitz LA
    J Am Geriatr Soc; 1996 Apr; 44(4):394-9. PubMed ID: 8636583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R; Schechtman E; Nisipeanu P
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.
    Li MH; Mestre TA; Fox SH; Taati B
    J Neuroeng Rehabil; 2018 Nov; 15(1):97. PubMed ID: 30400914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
    Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
    J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
    Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
    J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A group intervention to improve quality of life for people with advanced dementia living in care homes: the Namaste feasibility cluster RCT.
    Froggatt K; Best A; Bunn F; Burnside G; Coast J; Dunleavy L; Goodman C; Hardwick B; Jackson C; Kinley J; Davidson Lund A; Lynch J; Mitchell P; Myring G; Patel S; Algorta GP; Preston N; Scott D; Silvera K; Walshe C
    Health Technol Assess; 2020 Jan; 24(6):1-140. PubMed ID: 31971506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical predictive factors of subthalamic stimulation in Parkinson's disease.
    Welter ML; Houeto JL; Tezenas du Montcel S; Mesnage V; Bonnet AM; Pillon B; Arnulf I; Pidoux B; Dormont D; Cornu P; Agid Y
    Brain; 2002 Mar; 125(Pt 3):575-83. PubMed ID: 11872614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinsonian axial signs in schizophrenia.
    Morgante F; Barbui C; Tinazzi M;
    Parkinsonism Relat Disord; 2017 Mar; 36():89-92. PubMed ID: 28038867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.